Conquer Fear: The development and pilot testing of a novel psychological treatment for fear of cancer recurrence by Thewes, B et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This is the peer reviewed version of the following article: Belinda Thewes, Melanie 
Bell, Alan Ben Smith, Joanna Fardell, Jane Turner, Phyllis Butow, the PoCoG FCR 
Working Group. Conquer Fear: The development and pilot testing of a novel 
psychological treatment for fear of cancer recurrence. Asia Pacific Journal of Clinical 
Oncology 2012; 8(Suppl 3):207. Which has been published in final form at DOI: 
10.1111/ajco.12029 
CONQUER FEAR: THE DEVELOPMENT AND PILOT TESTING OF A  
NOVEL PSYCHOLOGICAL TREATMENT FOR FEAR OF CANCER  
RECURRENCE 
 
Belinda Thewes1, Melanie Bell2, Alan Ben Smith1, Joanna Fardell1, Jane Turner3, 
Phyllis Butow1, the PoCoG FCR Working Group2 
 
1.  School of Psychology, University of Sydney, Camperdown, NSW,  
Australia 
2.  Psycho-Oncology Cooperative Research Group of Australia (PoCoG),  
University of Sydney, Sydney, NSW, Australia 
3.  School of Medicine, University of Queensland, Brisbane, Queensland, Australia 
 
Although 26–56% of cancer survivors report moderate to high levels of need for help 
with fear of cancer recurrence (FCR), there are currently few FCR-specific treatments 
available. 
 
Aims: To describe the development and evaluation of a novel 5-session therapist-
delivered psychological intervention for FCR in cancer survivors. 
 
Methods: The manualised intervention was developed by clinicians from the Psycho-
Oncology Cooperative Research Group (PoCoG) and was based on the Common 
Sense Model of Illness, Self-Regulatory Executive Function Model (S-REF) and 
Relational Frame Theory. Eight experienced clinical psychologists and one 
psychiatrist completed a 1-day training session. Eli-gibility criteria for the pilot 
included: diagnosis with prostate, breast or colorectal cancer, completed hospital-
based treatment at least 2 months prior, no active disease, and a score of 13 or higher 
on the FCRI Severity Index. Data were collected pre-treatment, at treatment 
completion and 2 months post-treatment. 
 
Results: Of the recruited 8 patients all completed the intervention, and on average 
reported a decrease in FCR of 8.2 points on the 36-point FCR severity subscale (p = 
0.002, effect-size 1.9); an increase in Quality of life of 13.0 points on the 100-point 
FACT-G (p = 0.2, effect-size 0.67) and a decrease of 17.7 points on the 75-point 
impact of events scale (p = 0.03, effect-size 1.2). Patients rated the helpfulness of the 
therapy on average as 8/10 for treating their FCR. All therapists agreed that the 
training was informative, of appropriate length and applicable to their clinical 
practice. Confidence in treating FCR increased from 5.7 pre-training to 8 post-training 
(where 10 represents highest confidence).  
 
Conclusions: Although this is one-armed study with a very small sample size, the 
patient and therapist pilot data indicate the likely success of this intervention. This 
abstract could form part of the symposium proposal titled ‘An inter-national 
perspective on advances in the treatment of Fear of Cancer Recurrence’ 
 
